Meet #BioPhy Co-Founder, Chief Executive & Scientific Officer, Dave Latshaw II. Dave, along with BioPhy's other co-founders, is an alumnus of the #Wharton School. Before joining BioPhy, Dave built and scaled nationally recognized #AI programs at Janssen (J&J).

Today we’d like to introduce you to BioPhy Co-Founder, President and Chief Financial Officer, Steve Truong. Steve, along with BioPhy's other co-founders, is an alumnus of the Wharton School. instagram.com/p/CJeO06tpURZ/…

Meet BioPhy Co-Founder & Chief Medical Officer Dr. Daniel Sciubba, professor of neurological surgery, oncology, & orthopaedic surgery at the Johns Hopkins University School of Medicine. He serves as Director of spine tumor & spinal deformity research in the Dept. of Neurosurgery.

BioPhy’s quantifiable & scalable approach to investment is AI-based, continually running & improving. Our AI engine has shown the ability to predict the success & failure of clinical trials in Phases 1, 2, & 3. This allows biotech investors to make informed investment decisions.

Our #AI engine has demonstrated the ability to predict the likelihood of #clinicaltrial success. What does this mean for the future of healthcare & biotech investing? Faster, cheaper, more life-changing medical breakthroughs, along w/ reduced risk of investment decisions.

Biotech is a large area of asset management. The number of clinical trials is growing- but biotech investing is often still unpredictable, volatile & risky. We apply our AI-driven insights, using finance, to deliver meaningful &aligned outcomes for patients, investors & doctors.

Clinical trial success is risky, uncertain, & unclear. With four stages of clinical trials, the process can take many years & millions of dollars to complete. What if you could predict the outcomes of clinical trials? We can. Visit BioPhy.ai for more information.

Individuals in every industry impacted by #clinicaltrials struggle to make good decisions with little information due to the unpredictable outcomes of trials. By using BioPhy's #AI-driven engine, we can provide impacted industries data-driven solutions to their challenges.

By using AI to predict clinical trial successes, BioPhy can inform development decisions, identify high and low probabilities of success, and, most importantly, connect patients to life-saving treatments. sources: theconversation.com biophy.ai

Because of the COVID-19 pandemic there has been an increase in remote data collection in #clinicaltrials, which will create even more opportunity for #artificialintelligence in clinical trial prediction. lnkd.in/ec8m-ZA

BioPhy’s #AI model can see and build connections between seemingly disparate information that humans cannot. By using these insights, BioPhy can help #investors make informed decisions and connect them to high-conviction #opportunities.

#AI is revolutionizing healthcare in countless ways. We believe we can continue to transform it by using artificial intelligence to predict clinical trial successes, which can inform development decisions & help connect patients to live-saving treatments. lnkd.in/eAAXA9gmp

Meet our Quantitative Data Scientist Tejas Krishna Reddy!

BioPhy Tejas is a highly valued member of our team!

Today we’d like to introduce you to BioPhy General Counsel, Caitlin Jaye-Yan.

#Clinicaltrial outcomes are a key input to biotech valuations. It’s very difficult to predict likely outcomes of trials- until now. Biophy has developed an #AI-model that predicts the likely outcome of clinical trials.

By using our AI-platform to predict the success and failure of clinical trials, Biophy can raise awareness among doctors and patients about which trials are most likely to succeed, allowing them to make informed decisions about clinical trial participation.

At Biophy, we are driven by our promise to deliver hope. By applying our AI-driven insights to finance, we can deliver meaningful outcomes for patients, investors and doctors. #ai #healthcare #artificialintelligence #finance #research #biotech #startup #clinicaltrials #investing

instagram.com/p/CLK-WAZp1vY/…

Steve Truong, David Latshaw, and Dr. Dan Sciubba (all WG’21) teamed up in the #WhartonEMBA program around a goal to “fight cancer with finance.” #WhartonGrad At the end of 2019, the cofounders officially launched BioPhy, a health care fintech firm: whr.tn/3ilrz5E